Please login to the form below

Not currently logged in
Email:
Password:

Genzyme’s Richard Moscicki joins FDA

Provides regulatory agency with more than 20 years of industry experience

FDA, Richard MoscickiThe US Food and Drug Administration (FDA) has appointed Genzyme's Dr Richard Moscicki to the newly created position of deputy centre director for science operations at its Center for Drug Evaluation and Research (CDER).

Dr Moscicki, who currently serves as senior VP, head of clinical development at Sanofi's Genzyme division, will help lead the CDER in its role to regulate over-the-counter and prescription-only drugs available in the US.

The FDA will benefit from his strong industry background in research, which includes time spent as medical director and chief medical officer at Genzyme.

He also gained regulatory and pharmacovigilance experience at the US-based biotech, serving as its senior VP of biomedical and regulatory affairs from 1996 to 2011.

In his role at the FDA, Dr Moscicki will work with Dr Bob Temple, deputy director for clinical science, and Dr Doug Throckmorton, deputy director for regulatory programmes.

14th February 2013

From: Research, Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...